成大生物(688739.SH)：流感病毒裂解疫苗(高剂量)获得药物临床试验批准通知书

Core Viewpoint - Chengda Biological (688739.SH) has received approval from the National Medical Products Administration for clinical trials of a high-dose influenza virus split vaccine [1] Group 1: Company Developments - Chengda Biological's wholly-owned subsidiary, Chengda Biological (Benxi) Co., Ltd., has been granted a clinical trial approval notice for the high-dose influenza virus split vaccine [1] - The vaccine is developed using the influenza virus strains recommended by the World Health Organization (WHO) and contains four times the effective components compared to the conventional dose [1]